2-cyclopropyl-3,3-dimethyl-butan-2-ol | 24230-09-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-cyclopropyl-3,3-dimethyl-butan-2-ol
• 英文别名: Cyclopropyl-methyl-tert.-butyl-carbinol；tert-Butyl-cyclopropyl-methyl-carbonium；3,3-Dimethyl-2-cyclopropyl-butanol-(2)；2-Cyclopropyl-3,3-dimethylbutan-2-ol
• CAS: 24230-09-9
• 化学式: C₉H₁₈O
• 分子量: 142.241
• InChiKey: ATQVMXPZGIGTAJ-UHFFFAOYSA-N

物化性质

• 沸点：
  85 °C(Press: 45 Torr)
• 密度：
  0.886 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  甲基碘化镁 、 cyclopropyl tert-butyl ketone 在 乙醚 作用下， 生成 2-cyclopropyl-3,3-dimethyl-butan-2-ol
  参考文献：
  名称：

  t-Butyl Cyclopropyl Ketone¹

  摘要：

  DOI：

  10.1021/ja01629a059

文献信息

• GSK-3 INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160272621A1

  公开（公告）日：2016-09-22

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.

  本发明涉及公式I的化合物及其盐，以及使用这些化合物治疗与GSK-3相关的疾病的组合物和方法。
• Piperidine isoxazole and isothiazole orexin receptor antagonists
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US10017504B2

  公开（公告）日：2018-07-10

  The present invention is directed to piperidine isoxazole and isothiazole orexin compounds which are antagonists of orexin receptors. Such compounds are of the general structural formula I: wherein the variables are defined herein. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及哌啶异恶唑和异噻唑奥曲肽化合物，它们是奥曲肽受体的拮抗剂。此类化合物的结构通式为 I： 其中变量的定义见本文。 本发明还涉及本文所述化合物在潜在治疗或预防涉及奥曲肽受体的神经和精神疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在预防或治疗涉及奥曲肽受体的此类疾病中的用途。
• Meschtscherjakow; Gluchowzew, Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya, 1958, p. 780,781; engl.Ausg.S. 758, 759
  作者：Meschtscherjakow、Gluchowzew

  DOI：——

  日期：——
• Stable Carbonium Ions. XVII.^1a Cyclopropyl Carbonium Ions and Protonated Cyclopropyl Ketones
  作者：Charles U. Pittman、George A. Olah

  DOI：10.1021/ja00950a026

  日期：1965.11
• PIPERIDINE OXADIAZOLE AND THIADIAZOLE OREXIN RECEPTOR ANTAGONISTS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20170313693A1

  公开（公告）日：2017-11-02

  The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.